Research
Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) produce significantly greater weight loss (10-20%+) compared to other anti-obesity medications (3-7%) and placebo.
If lifestyle changes are not enough, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Mounjaro) offer the highest weight loss potential (10-20%). These are injectable medications typically used when BMI is >30 (or >27 with comorbidities). They work by reducing appetite and slowing digestion. Consult a physician to see if you qualify.
StrongSupportsVERY_HIGH confidence
GLP- 1 receptor agonists semaglutide and tirzepatide appear to be significantly more efficient than other classes of medications. Semaglutide at 2.4 mg and tirzepatide at doses of 10 g and 15 mg can help patients reduce their body weight by more than 10%.
Why this rating
Based on large clinical trials (e.g., 803 participants for semaglutide, 2539 for tirzepatide) cited in the review.
Source
Review on obesity management: diet, exercise and pharmacotherapy
Katya Peri et al. · BMJ Public Health · 2024
narrative_reviewCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →